Catalyst Wire Dossier Catalyst Wire Dossier

Verubecestat

MK-8931 · Merck Sharp & Dohme LLC
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for Verubecestat, covering 2015-01-26 to 2019-05-17. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019) [Phase 3]

See pricing